Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
Halberd Corporation (OTC: HALB) completed a live technical feasibility demonstration of its NeuroSense AI behavioral analysis platform on Oct 27, 2025. The demo validated core technologies and real-time multi-modal processing, showing capability to capture professional-grade behavioral data, extract vocal and movement features, generate automated assessments and visualizations, and integrate with Claude AI (Anthropic) for pattern interpretation.
Halberd said the platform remains in active development with phased next steps: component integration (3–4 months), advanced algorithm work (3–4 months), clinical interface build (2–3 months), and production deployment (2–3 months). The company highlighted the need for rigorous validation studies, peer-reviewed results, and regulatory pathway work before commercial deployment.
Halberd Corporation (OTC: HALB) ha completato una dimostrazione live di fattibilità tecnica della sua piattaforma di analisi comportamentale AI NeuroSense il 27 ottobre 2025. La demo ha validato le tecnologie di base e l'elaborazione multi-modale in tempo reale, dimostrando la capacità di catturare dati comportamentali di livello professionale, estrarre caratteristiche vocali e di movimento, generare valutazioni e visualizzazioni automated e integrarsi con Claude AI (Anthropic) per l'interpretazione dei pattern.
Halberd ha dichiarato che la piattaforma rimane in sviluppo attivo con passaggi successivi in fase: integrazione dei componenti (3–4 mesi), lavoro avanzato sugli algoritmi (3–4 mesi), sviluppo dell'interfaccia clinica (2–3 mesi) e distribuzione in produzione (2–3 mesi). L'azienda ha evidenziato la necessità di studi di convalida rigorosi, risultati peer-reviewed e lavoro sul percorso normativo prima della commercializzazione.
Halberd Corporation (OTC: HALB) completó una demostración en vivo de viabilidad técnica de su plataforma de análisis conductual IA NeuroSense el 27 de octubre de 2025. La demostración validó tecnologías centrales y procesamiento multmodal en tiempo real, mostrando la capacidad de capturar datos conductuales de calidad profesional, extraer características vocales y de movimiento, generar evaluaciones y visualizaciones automatizadas, e integrar con Claude AI (Anthropic) para la interpretación de patrones.
Halberd indicó que la plataforma continúa en desarrollo activo con próximos pasos por fases: integración de componentes (3–4 meses), trabajo avanzado de algoritmos (3–4 meses), construcción de la interfaz clínica (2–3 meses) y despliegue en producción (2–3 meses). La empresa destacó la necesidad de estudios de validación rigurosos, resultados revisados por pares y trabajo en la ruta regulatoria antes de la comercialización.
Halberd Corporation (OTC: HALB)은 NeuroSense AI 행동 분석 플랫폼의 실시간 기술 타당성 시연을 2025년 10월 27일에 완료했습니다. 이번 시연은 핵심 기술과 실시간 다중 모달 처리를 검증했으며, 전문급 행동 데이터를 포착하고, 음성 및 운동 특징을 추출하며, 자동 평가 및 시각화를 생성하고, 패턴 해석을 위해 Claude AI (Anthropic)와의 통합이 가능함을 보여주었습니다.
Halberd는 플랫폼이 현재 활발히 개발 중이며 단계별 다음 단계를 제시했습니다: 구성요소 통합(3–4개월), 고급 알고리즘 작업(3–4개월), 임상 인터페이스 구축(2–3개월), 생산 배포(2–3개월). 회사는 상용 배포 전에 엄격한 검증 연구, 동료 심사 결과, 규제 경로 작업의 필요성을 강조했습니다.
Halberd Corporation (OTC: HALB) a réalisé une démonstration de faisabilité technique en direct de sa plateforme d'analyse comportementale IA NeuroSense le 27 octobre 2025. La démonstration a validé les technologies centrales et le traitement multi-modal en temps réel, montrant la capacité à capturer des données comportementales de niveau professionnel, à extraire des caractéristiques vocales et de mouvement, à générer des évaluations et des visualisations automatisées, et à s’intégrer avec Claude AI (Anthropic) pour l’interprétation des motifs.
Halberd indique que la plateforme est toujours en développement actif avec des étapes suivantes par phase: intégration des composants (3–4 mois), travail avancé sur les algorithmes (3–4 mois), construction de l’interface clinique (2–3 mois) et déploiement en production (2–3 mois). L’entreprise souligne la nécessité d’études de validation rigoureuses, de résultats évalués par des pairs et de travaux sur le chemin réglementaire avant le déploiement commercial.
Halberd Corporation (OTC: HALB) hat am 27. Oktober 2025 eine Live-Demonstration der technischen Machbarkeit ihrer NeuroSense KI-Verhaltensanalyse-Plattform abgeschlossen. Die Vorführung validierte Kerntechnologien und die Echtzeit-Mehrkanalverarbeitung, zeigte die Fähigkeit, professionell hochwertige Verhaltensdaten zu erfassen, Stimm- und Bewegungsmerkmale zu extrahieren, automatisierte Bewertungen und Visualisierungen zu erzeugen und sich mit Claude AI (Anthropic) zur Musterinterpretation zu integrieren.
Halberd erklärte, dass die Plattform sich weiterhin in aktiver Entwicklung befindet mit phasenweisen nächsten Schritten: Komponentenintegration (3–4 Monate), fortgeschrittene Algorithmusarbeit (3–4 Monate), Aufbau der klinischen Oberfläche (2–3 Monate) und Produktionsbereitstellung (2–3 Monate). Das Unternehmen hob die Notwendigkeit rigoroser Validierungsstudien, peer-reviewed Ergebnisse und regulatorischer Wegbereitschaft vor der kommerziellen Einführung hervor.
Halberd Corporation (OTC: HALB) أكملت عرضاً حيّاً لقدرة فنية ضمن منصة NeuroSense للتحليل السلوكي بالذكاء الاصطناعي في 27 أكتوبر 2025. أكّدت التجربة صحة التقنيات الأساسية ومعالجة متعددة الوسائط في الوقت الفعلي، مبيّنة القدرة على التقاط بيانات سلوكية بمستوى احترافي، واستخراج سمات صوتية وحركية، وتوليد تقييمات وتصورات آلية، والاندماج مع Claude AI (Anthropic) لتفسير الأنماط.
وقالتHalberd إن المنصة ما تزال قيد التطوير النشط مع خطوات مقسمة على النحو التالي: تكامل المكونات (3–4 أشهر)، عمل خوارزميات متقدم (3–4 أشهر)، بناء واجهة عيادية (2–3 أشهر)، ونشر الإنتاج (2–3 أشهر). وأكدت الشركة على ضرورة إجراء دراسات تحقق صارمة، ونتائج مقيمة من أقران، والعمل على مسار تنظيمي قبل الإطلاق التجاري.
Halberd Corporation (OTC: HALB) 已在< b>2025年10月27日完成其 NeuroSense AI 行为分析平台的现场技术可行性演示。演示验证了核心技术和实时多模态处理，展示了捕捉专业水平的行为数据、提取声学和运动特征、生成自动化评估与可视化，以及与 Claude AI (Anthropic) 的模式解释集成能力。
Halberd 表示，该平台仍在积极开发中，未来分阶段的下一步为：组件集成（3–4 个月）、高级算法工作（3–4 个月）、临床界面构建（2–3 个月）以及生产部署（2–3 个月）。公司强调在商业部署前需要进行严格的验证研究、同行评审结果以及监管路径工作。
- Live technical demonstration completed on Oct 27, 2025
- Core technologies validated: real-time multi-modal processing
- Demonstrated Claude AI integration for behavioral interpretation
- Established development timeline with phased 2–4 month milestones
- Platform not ready for commercial deployment; significant validation required
- Requires rigorous validation studies and peer-reviewed publication before market entry
- Regulatory pathway for clinical applications remains to be developed
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies
JACKSON CENTER, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence.
Successful Technical Demonstration
In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to:
- Capture and process real-time behavioral data with professional-grade accuracy
- Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics)
- Generate automated behavioral assessments and visualizations
- Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms
"The demonstration exceeded our expectations," said William Hartman, CEO of Halberd Corporation. "Seeing the core technology working in real-time – capturing data, analyzing patterns, and generating insights within seconds – validated our confidence in this platform's potential to transform TBI research."
Technology Validation Milestone
The successful demonstration represents a critical development milestone, confirming that:
Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns.
Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.
Multi-Modal Integration Is Feasible: The demonstration validated the technical approach to combining multiple data streams (vocal, movement, social) into unified behavioral assessments.
Clinical Advisor Engagement
The demonstration was conducted for the Halberd Team who are evaluating potential advisory roles for the platform's clinical development and validation strategy. Their expertise will be instrumental in designing validation protocols and establishing research partnerships.
"Having clinical expertise involved at this early stage ensures that our platform properly and efficiently addresses real research needs and follows appropriate validation pathways, while adhering to established protocols," noted a member of the development team. "The technical demonstration helped our clinical advisors understand both the platform's capabilities and its potential applications in TBI research."
Development Status and Timeline
NeuroSense AI is currently in active development following successful proof-of-concept validation:
Current Status:
- Core technical architecture validated through live demonstration
- Multi-modal data processing capabilities confirmed
- AI integration approach proven feasible
- Development environment established and operational
Next Development Phases:
- Complete integration of all platform components (3-4 months)
- Advanced behavioral analysis algorithm development (3-4 months)
- Clinical interface and reporting system (2-3 months)
- Production deployment and optimization (2-3 months)
Technology Foundation
The platform's technical approach combines proven commercial technologies:
Data Processing: Professional-grade audio and video analysis using industry-standard scientific computing frameworks
AI Analysis: Claude AI integration (Anthropic) for advanced pattern recognition and behavioral interpretation
Infrastructure: Cloud-native architecture supporting scalable deployment from single-subject studies to large multi-site trials
Interface: Modern web-based dashboard for real-time monitoring and historical analysis
Investor and Stakeholder Communication
"We're sharing this update with our shareholders because the successful demonstration represents tangible progress," said Hartman. "While we remain early in development, we've now proven the technical feasibility of our approach. This isn't vaporware or just a concept – we have working technology that demonstrates the platform's core capabilities. Perhaps even more significantly, this technology can be used in research endeavors, even unrelated to workload pursuits involving traumatic brain injury and other medical maladies."
The company emphasized that significant work remains before the platform is ready for commercial deployment, including:
- Complete platform integration and testing
- Rigorous validation studies with research partners
- Peer-reviewed publication of validation results
- Regulatory pathway development for clinical applications
Transparency and Realistic Expectations
Halberd maintains transparency regarding the platform's development status:
What Exists Now: Working technology demonstrating core capabilities and technical feasibility
What's Being Built: Complete integrated platform with all features, interfaces, and deployment capabilities
What's Required for Validation: Rigorous scientific validation through research partnerships and peer-reviewed publication
What's Needed for Market Entry: Established clinical evidence, research adoption, and demonstrated utility in actual studies
Next Steps
Immediate Focus:
- Implementation of next steps in TBI research initiative with Mississippi State University
- Continue platform development on established timeline
- Finalize clinical advisory board membership
- Advance research partnership discussions
- Submit grant applications for validation funding
Upcoming Milestones:
- Complete development documentation and architecture finalization
- Demonstrate expanded platform capabilities
- Announce research partnership agreements
- Initiate pilot validation studies
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
X:@HalberdC
About NeuroSense AI
NeuroSense AI is a behavioral intelligence platform in development by Halberd Corporation, designed to transform preclinical TBI research through multi-modal behavioral analysis and advanced AI interpretation. The platform combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered pattern recognition to provide objective, continuous assessment of neurological function and recovery. For more information, visit NeuroSenseAI.ai
About Halberd Corporation
Halberd Corporation (OTC: HALB) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company's portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation's business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
FAQ
What did Halberd (HALB) demonstrate with NeuroSense AI on Oct 27, 2025?
What is the expected Halberd (HALB) development timeline for NeuroSense AI?
Does the NeuroSense AI platform have commercial readiness or regulatory approval now?
How does Halberd plan to validate NeuroSense AI for clinical use (HALB)?
What technical capabilities did Halberd confirm for NeuroSense AI (HALB)?
